Belantamab Mafodotin or Daratumumab for Multiple Myeloma

(PrE1005 Trial)

This trial explores two treatment combinations for individuals with newly diagnosed multiple myeloma, a type of blood cancer. The researchers aim to determine if belantamab mafodotin, a targeted therapy that delivers a cell-killing toxin directly to cancer cells, can improve outcomes compared to daratumumab, another treatment option. Ideal participants have not received a bone marrow transplant, may have declined it, and are experiencing symptoms of multiple myeloma, such as abnormal protein levels in the blood or urine. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to the development of a promising new treatment.

Research has shown that belantamab mafodotin, a targeted cancer treatment, is generally well-tolerated, though some side effects are common. It has proven effective in treating multiple myeloma, even for patients unresponsive to other treatments. However, one study found that eye problems affected 75% of patients, with about 33% experiencing more serious issues.

Eye-related side effects are the most reported but are usually manageable. Regular eye check-ups are important during this treatment. Despite these side effects, belantamab mafodotin has demonstrated a significant survival benefit for patients with multiple myeloma.

Daratumumab, another treatment option in the trial, is well-tolerated by many patients. The FDA has already approved it for treating multiple myeloma, indicating a strong safety profile. Common side effects include tiredness and nausea, but these are usually mild.

Researchers are excited about Belantamab Mafodotin for multiple myeloma because it represents a novel approach to targeting cancer cells. Unlike traditional therapies, Belantamab Mafodotin is an antibody-drug conjugate that delivers a toxic payload directly to the cancer cells, potentially reducing harm to healthy cells. This targeted action could lead to fewer side effects and more effective treatment outcomes. Meanwhile, Daratumumab, another treatment in the trial, is a monoclonal antibody that works by recruiting the immune system to attack and destroy multiple myeloma cells, offering a different mechanism of action compared to standard chemotherapy options.

Research has shown that belantamab mafodotin, which participants in this trial may receive, may effectively treat multiple myeloma. Specifically, studies reported that 66.7% of patients experienced a reduction or disappearance of their cancer. In this trial, belantamab mafodotin will be combined with other drugs like bortezomib and dexamethasone. Another group of participants will receive daratumumab, a well-known treatment that extends patient survival when combined with other therapies. Both treatments are effective against multiple myeloma, with belantamab mafodotin offering a new, targeted approach.⁶⁷⁸⁹¹⁰